European Healthtech, MedTech and Health AI IPO Outlook: Top 10 Listing Candidates for 2026, 2027, 2028

Nelson Advisors
2 hours ago
16 min read

The European healthcare technology, medical devices (Medtech), and artificial intelligence (Health AI) ecosystems have transitioned from post-pandemic venture fragmentation into a disciplined era of industrial maturity.

Following a severe liquidity drought that curtailed capital deployment and delayed public listings between late 2021 and 2024, the public offering window is reopening under fundamentally altered underwriting standards. Institutional public equity allocators no longer subsidise top line growth at the expense of cash preservation; market receptivity is now governed by positive free cash flow trajectories, regulatory compliance moats, high gross margins and defensible clinical validation.

Within this recalibrated environment, late stage European scale-ups face strategic structural decisions, weighing the deeper institutional capital pools and valuation premiums of United States exchanges against overhauled, founder friendly domestic listing regimes across London and Continental Europe.

Macroeconomic Inflection, Regulatory Moats and Public Underwriting Criteria

The macroeconomic environment entering the 2026–2027 cycle has stabilised as central bank monetary easing lowers sovereign bond yields, enhancing the relative appeal of high growth equities and reopening institutional exit pathways.

However, public market investors retain acute memories of the speculative digital health boom and subsequent valuation contractions of 2021 to 2023, resulting in a persistent pricing gap between legacy enterprise software and early stage healthtech issuers. To bridge this trust gap, underwriting syndicates have established concrete financial hurdles across distinct sub-verticals.

Metric	Medtech & Surgical Robotics	Healthtech SaaS & Digital Platforms	Health AI & Computational Precision Medicine
Minimum ARR / Annual Run-Rate	$40M – $60M+	$200M+	$50M – $100M+ (Licensing & Royalties)
Target Gross Margin Profile	65% – 80%	60% – 80%+	75% – 90%
Required 2–3 Year CAGR	25% – 30%+	20% – 25%+	35% – 50%+
Profitability Baseline	Clear EBITDA-positive horizon	Adjusted EBITDA / FCF breakeven	High-margin operating cash flow leverage
Primary Regulatory Prerequisite	FDA 510(k)/PMA & EU MDR Class II/III	FDA Class I/II & DiGA / CE Mark	HIPAA, GDPR, & GxP-compliant clinical data

Beyond financial benchmarks, the structural viability of European candidates is dictated by regulatory barriers to entry. The rigorous implementation of the European Union Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has precipitated an environment of regulatory Darwinism.

While compliance requires substantial capital deployment, companies that have secured Class IIb or Class III MDR certifications and corresponding United States Food and Drug Administration (FDA) 510(k) or De Novo clearances have erected formidable competitive barriers. These regulatory assets insulate market share, sustain pricing power, and de-risk post-IPO revenue projections against venture backed market entrants.

Simultaneously, enterprise value in Health AI has migrated away from commoditized large language models toward vertical platform operators controlling proprietary, multimodal clinical databases.

Companies that integrate real-world evidence, histopathology, federated hospital networks and predictive care workflows command significant funding premiums and public market interest, driven by their ability to generate high-margin software revenues directly tied to measurable clinical outcomes and workflow efficiencies.

Primary European IPO Candidates Across Healthtech, Medtech and Health AI

The late-stage pipeline is led by ten companies that have reached critical scale, established defensible clinical and regulatory assets, and demonstrated concrete indicators of capital market readiness.

Company	HQ	Founding Year	Subsector & Core Platform	Total Funding Raised	Latest Private Valuation	Key Benchmarks	Anticipated Exchange & Timeline
Oura Health	Oulu, Finland	2013	Healthtech / AI Biometrics & Smart Rings	~$1.3B+	$11.0B (private); targeting $16.0B+ IPO	~$1.0B revenue (2025); targeting $2.0B sales (2026); profitable	NASDAQ (Late 2026)
Doctolib	Paris, France	2013	Digital Health / SaaS Practice Management & Clinical AI	~$900M	~$6.4B (€5.8B)	€348M ARR (2024), scaling to €450M+; core French operations profitable	Euronext Paris or NASDAQ (2026–2027)
CMR Surgical	Cambridge, UK	2014	Medtech / Versius Soft-Tissue Surgical Robotics	~$1.2B	$3.0B – $4.0B	Installed base >1,000 systems; >30,000 surgical procedures; Ely plant operating	LSE or NASDAQ (Dual-Track / 2026–2027)
Alan	Paris, France	2016	Insurtech & Healthtech / Digital "Prevention Insurance" & AI Platform	~$1.1B	€5.5B ($6.3B)	>€800M ARR (+53% YoY); breakeven in France; group profitability targeted by 2027	Euronext Paris or US (Late 2026–2027)
Sword Health	Porto, Portugal / US	2015	Health AI / Musculoskeletal (MSK) Digital Therapy & AI Care	~$500M	$4.0B	$240M revenue run-rate; cash-flow positive; accretive M&A (Kaia Health, Headspace)	NASDAQ (2026–2027)
Owkin	Paris, France	2016	Health AI / Federated Learning & Computational Biopharma	~$300M+	$1.0B+	Multi-year high-margin licensing pacts (Sanofi, AstraZeneca, Boehringer)	NASDAQ (Late 2026–2027)
Huma Therapeutics	London, UK	2011	Digital Health / Remote Patient Monitoring & Cloud Infrastructure	~$300M+	~$1.0B	Regulated platform (FDA Class II, MDR Class IIb); strategic enterprise contracts	London Stock Exchange (2026–2027)
Cera Care	London, UK	2015	Health AI / Tech-Enabled Home Care & Predictive Triage	~$715M	~$1.0B+	$500M annualized revenue; 2.5M visits/month; 150+ public NHS contracts	LSE or US listing (2026–2027)
Neko Health	Stockholm, Sweden	2018	Medtech & Health AI / Preventative Full-Body 3D Diagnostics	~$960M	$7.0B	High clinical demand (100k waitlist); rapid commercial rollout in EU and US	NASDAQ or NYSE (2027)
Distalmotion	Lausanne, Switzerland	2012	Medtech / Dexter Hybrid Robotic Surgery for Outpatient ASCs	~$390M	~$800M – $1.2B	CE mark and FDA clearances secured; targeted positioning in high-margin US ASCs	NASDAQ or SIX Swiss Exchange (2026–2027)

Oura Health

Oura Health has transformed from a premium consumer wearable brand into an integrated biometric intelligence and preventative medical technology enterprise. The company's hardware architecture, the Oura Ring, utilises miniaturised photoplethysmography sensors, negative temperature coefficient thermistors and 3D accelerometers to capture continuous physiological data, which its machine learning algorithms translate into actionable sleep, cardiovascular, and metabolic insights. Oura has raised over $1.3 billion in venture and growth capital, with its capitalisation anchored by an $875 million to $900 million Series E round led by Fidelity Management & Research Company, which initially set its private mark at $11 billion.

The business has established a dual-revenue engine combining hardware sales with recurring, high-margin software subscriptions. Financial performance accelerated through 2025, generating approximately $1.0 billion in revenue, representing a doubling of its 2024 results and setting guidance for $2.0 billion in sales for 2026 on sustained net profitability.

Concrete public offering preparations were initiated on May 21, 2026, when Oura submitted a confidential draft registration statement on Form S-1 with the United States Securities and Exchange Commission. The company assembled an underwriting syndicate comprising Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Company, and Jefferies, with institutional indications suggesting a public target valuation exceeding $16 billion. Led by Chief Executive Officer Tom Hale, Oura is positioned to list on NASDAQ in late 2026, serving as a primary pricing reference for the global digital health sector.

Doctolib

Doctolib operates the dominant digital health infrastructure in continental Europe, providing cloud-based practice management software, patient appointment scheduling, digital prescription distribution, and secure telehealth connectivity. The platform accounts for 80 million patient profiles and connects over 900,000 healthcare practitioners across France, Germany, and Italy.

The company's valuation reached €5.8 billion ($6.4 billion) following a €500 million equity and debt financing round in 2022 backed by Eurazeo, General Atlantic, Bpifrance, and Accel. Rather than pursuing further dilutive primary rounds during the tech correction, Doctolib managed secondary liquidity with long-term crossover investors including Generation Investment Management.

The enterprise's financial trajectory reflects disciplined cost rationalization and successful geographic scaling. Group-wide adjusted EBITDA losses narrowed from €87.1 million in 2023 to €53.8 million in 2024, supported by profitability in its core French domestic market. ARR expanded from €348 million in 2024 toward run-rates exceeding €420 million to $450 million in 2025–2026. Margin expansion has been further supported by the introduction of an AI-powered ambient clinical documentation assistant that automates administrative workflows for physicians.

Under Chief Financial Officer Pierre Vergnes and Chief Executive Officer Stanislas Niox-Chateau, Doctolib possesses the scale and recurring cash flow required for a flagship initial public offering. While Euronext Paris has positioned itself as the logical domestic exchange, management has evaluated a dual-listing structure with NASDAQ to secure comparable multiples alongside United States vertical SaaS peers, with a public offering projected between late 2026 and 2027.

CMR Surgical

CMR Surgical develops the Versius surgical robotic system, an articulated, modular soft-tissue platform engineered to compete directly with Intuitive Surgical’s da Vinci by offering lower capital barriers to entry and operational mobility. Versius utilises independent, portable bedside arm carts that allow surgical teams to deploy robotics across standard operating suites without requiring permanent facility renovations.

The Cambridge based Medtech firm has secured roughly $1.2 billion in total equity and debt, supported by major investors including the SoftBank Vision Fund 2, Ally Bridge Group, Cambridge Innovation Capital, and Morgan Stanley Counterpoint Global, supplemented by a $200 million financing round co-anchored by Trinity Capital.

The commercial viability of Versius is supported by an operational base exceeding 1,000 installed systems globally, which have completed more than 30,000 clinical procedures across Europe, the Middle East, and Asia. The company cleared a major regulatory hurdle in mid-2025 by securing United States FDA clearance for Versius, complementing European CE mark expansions into pediatric abdominal procedures. Its Ely manufacturing facility provides the capacity to deliver 500 robotic consoles annually, driving recurring revenue through single-use surgical instruments, digital connectivity subscriptions, and service agreements.

Led by CFO Andre Nel and Executive Chairman Dan Moore, CMR is executing a dual-track strategy, preparing for an IPO valued between $3 billion and $4 billion on the London Stock Exchange or NASDAQ while reviewing strategic acquisition inquiries from global Medtech incumbents such as Medtronic, Johnson & Johnson, or Stryker, with an exit expected in late 2026 or 2027.

Alan

Alan is a licensed digital health insurer in continental Europe that pairs statutory and complementary corporate insurance with an AI-driven healthcare super-app providing 24/7 clinical navigation, proactive wellness programs and automated claims processing.

The Paris headquartered company operates across France, Spain, Belgium, and Canada, covering more than one million insured members across 37,000 enterprise accounts. Alan completed a €480 million Series G round in 2026 led by Prosus, alongside Index Ventures and Teachers' Venture Growth, raising its valuation to €5.5 billion ($6.3 billion).

Alan's operating model has generated significant top-line expansion, surpassing €800 million in ARR by early 2026, a 53% year over year increase, with management guiding toward more than €1.0 billion in run rate revenue. The business achieved operating breakeven in France in 2025 and is tracking enterprise wide consolidated group profitability by 2027 as international cohorts reach scale. Capitalising on its integration of proprietary generative AI workflows, Alan automates 70% of claims reimbursements within one hour while lowering overhead.

Co-founder and CEO Jean Charles Samuelian Werve has positioned the enterprise for public capital markets, actively assessing Euronext Paris and United States venues for a targeted public listing between late 2026 and 2027.

Sword Health

Sword Health delivers artificial intelligence native physical therapy and digital musculoskeletal (MSK) pain management. The platform couples medical-grade wearable kinematic motion sensors and digital tablet interfaces with its proprietary "Phoenix" clinical generative AI engine to track patient motion in real time, adjust therapeutic protocols and deliver immediate corrective guidance, under remote asynchronous supervision by licensed clinicians. Sword has raised approximately $500 million in aggregate financing, reaching a $4.0 billion valuation following a capital injection led by General Catalyst, alongside established backers including Khosla Ventures and Sapphire Ventures.

Sword has demonstrated rapid commercial execution, achieving positive operating cash flows alongside a recognised revenue run-rate exceeding $240 million. Annual revenues exceeded $200 million in 2025 and are projected to double in 2026, supported by direct payer partnerships and enterprise self-insured employer contracts.

The company has pursued strategic acquisitions, acquiring United Kingdom-based Surgery Hero to access the British National Health Service (NHS), German digital therapy competitor Kaia Health for $285 million to secure established reimbursement moats under Germany’s DiGA framework, and mental health company Headspace to form a unified physical-behavioral health platform. With primary competitor Hinge Health establishing public comparables in the United States, founder and CEO Virgilio Bento is potentially guiding Sword Health toward a NASDAQ listing between late 2026 and 2027.

Owkin

Owkin applies machine learning, predictive AI, and computational biology to oncology and immunology drug discovery. The company's core technological architecture relies on federated learning, a decentralised training mechanism that interrogates multi-institutional hospital electronic records, histopathology slides, and spatial omics data directly behind local institutional firewalls, enabling model training on massive patient datasets without centralising sensitive patient information.

Owkin achieved unicorn status with a private valuation over $1.0 billion following an equity investment from French pharmaceutical group Sanofi, supported by Alphabet’s GV, Bpifrance and Bristol-Myers Squibb.

The commercial model generates predictable, high-margin software revenues via enterprise licensing and milestone driven biopharma discovery partnerships. Sanofi structured a five year agreement in 2026 to license Owkin’s "K Pro" generative AI scientist platform across internal clinical programs. In addition, Owkin has secured multi-target development and real-world data collaboration pacts with AstraZeneca, Boehringer Ingelheim and Amgen.

Signaling formal public market preparations, the company appointed Andreas Emmenegger as Chief Financial Officer. Emmenegger brings two decades of capital markets leadership, having previously guided biopharma company Molecular Partners through initial public offerings on both the SIX Swiss Exchange and NASDAQ. With finance functions reinforced by Group CFO Bell, Owkin represents a qualified Health AI candidate for a late 2026 or 2027 NASDAQ listing.

Huma Therapeutics

Huma Therapeutics develops digital-first health infrastructure, enterprise remote patient monitoring (RPM) software, and digital clinical trial solutions for healthcare delivery networks and global pharmaceutical manufacturers. Its underlying architecture, the Huma Cloud Platform, functions as a modular software ecosystem that enables clinical institutions to deploy regulated, condition specific companion applications, gather digital biomarkers and automate acute triage protocols.

Huma has accumulated over $300 million in total funding, culminating in an $80 million Series D financing backed by AstraZeneca, Leaps by Bayer, Hitachi Ventures and Sony Innovation Fund, placing its valuation near the $1.0 billion mark.

Huma's technical differentiation is reinforced by significant regulatory assets, holding Class II medical device clearance from the United States FDA and Class IIb certification under the European MDR, establishing an effective moat against non-regulated software competitors. The company has pursued strategic inorganic expansion, acquiring primary care interface provider iPLATO, digital clinical triage provider eConsult, and United States respiratory AI platform Aluna, alongside formalizing joint technology initiatives with Fresenius Medical Care.

With placement advisory relationships previously led by Goldman Sachs and HSBC, Chief Executive Officer Dan Vahdat has structured Huma as a prime candidate for a London Stock Exchange listing in late 2026 or 2027, taking advantage of reformed listing standards on the LSE Main Market.

Cera Care

Cera Care operates an integrated technology-enabled home care and predictive healthcare platform across the United Kingdom, shifting high-acuity medical and social care from hospital wards into private residences. Cera equips its field workforce with proprietary machine learning applications that capture daily observational data, vital signs, and mobility metrics.

Its predictive algorithms analyse these clinical markers to detect deterioration up to 30-fold faster than standard clinical visits, preventing avoidable hospital admissions and generating operational efficiencies for public healthcare systems. Cera has secured approximately $715 million in equity and debt capital, including a $150 million financing round supported by institutional investors such as BDT & MSD Partners, Schroders Capital and Guinness Ventures.

The enterprise generates $500 million in annualized revenue, operating more than 150 local authority and NHS commissioning contracts while delivering 2.5 million home visits per month. Higher-margin non-home-care revenue divisions, encompassing digital clinical trials, care robotics through its acquisition of GenieConnect, and health data partnerships, surpassed $100 million in annualized revenues, accounting for 20% of aggregate sales.

Led by founder and CEO Dr. Ben Maruthappu and newly appointed Chief Technology and AI Officer Martin Samsa, Cera is executing governance and systems upgrades consistent with public market expectations. The company is positioned to pursue an IPO on the London Stock Exchange or a United States exchange during late 2026 or 2027.

Neko Health

Neko Health, co-founded by Spotify founder Daniel Ek and Hjalmar Nilsonne, is an automated preventative health scanning platform that combines medical imaging hardware, non-invasive optical scanning, and AI-driven clinical analytics. The platform’s proprietary 3D whole-body scanning system incorporates over 70 sensors to capture millions of clinical data points across cardiovascular performance, micro-circulation, systemic skin lesions, and metabolic risk indicators in an automated ten-minute clinical assessment.

Neko closed a €250 million Series B round in early 2025, followed by a $700 million (€612.7 million) Series C financing round in mid-2026 co-led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from Lakestar, Atomico and General Catalyst. The transaction raised the company's valuation to $7.0 billion.

Neko’s commercial centers in Stockholm and London have generated significant consumer traction, completing tens of thousands of preventative scans while maintaining waiting lists exceeding 100,000 paying individuals. The company is deploying its balance sheet to finance an international expansion into the United States, anchored by clinical diagnostic hubs in New York.

Given Daniel Ek's prior experience leading Spotify’s direct listing on the New York Stock Exchange, Neko is structurally designed to access United States public equity markets. Institutional allocators expect Neko to target a NASDAQ or NYSE public offering in 2027 once commercial unit economics and operational margins across its United States clinics are established at scale.

Distalmotion

Distalmotion is a medical device manufacturer based in Epalinges and Lausanne, Switzerland, that develops the "Dexter" robotic surgical system. Dexter is an open-architecture, mobile robotic console designed specifically for hospital outpatient departments and Ambulatory Surgery Centers (ASCs), rather than the multi-million-dollar inpatient suites targeted by legacy robotics platforms. The platform integrates wristed robotic instrumentation while preserving immediate bedside patient access, allowing surgeons to shift seamlessly between standard laparoscopic techniques and full robotic dexterity.

Distalmotion completed a $150 million Series G round led by Revival Healthcare Capital, followed by a strategic corporate investment from Johnson & Johnson Innovation (JJDC), bringing its aggregate funding to approximately $390 million and establishing a private valuation between $800 million and $1.2 billion.

Distalmotion holds clear regulatory clearances in key operating markets, including the European CE mark for urological, gynaecological, and general laparoscopic surgery, alongside United States FDA 510(k) clearances covering inguinal hernia repair, cholecystectomy, and benign hysterectomy. The company addresses the structural shift of surgical procedures out of acute care hospitals into high volume outpatient ASCs, where its smaller physical footprint and lower per procedure cost provide a compelling capital proposition.

Under Executive Chairman Chas McKhann and Chief Executive Officer Greg Roche, Distalmotion represents a viable public listing candidate. The company is managing a dual-track timeline pointing toward a late 2026 or 2027 flotation on NASDAQ or the SIX Swiss Exchange, alongside potential strategic buyout interest from global surgical conglomerates.

Comparative Capital Architecture and Strategic Listing Dynamics

The operational diversity of the top ten European candidates is reflected in their gross margins, capital intensity, and core revenue architectures.

Subsector Category	Representative Scaleups	Target Gross Margins	Regulatory & Clinical Moat	Primary Revenue Architecture
Connected Biometrics & Wearables	Oura Health	65% – 75%	Moderate; Consumer & FDA Class II clearances	Hardware margin + recurring consumer software SaaS
Digital Health SaaS & Platform Infrastructure	Doctolib, Huma Therapeutics	70% – 85%	Moderate / High; EU MDR Class IIb & FDA Class II	Provider enterprise software + platform APIs
Surgical Robotics & Medtech Systems	CMR Surgical, Distalmotion	60% – 70%	Very High; EU MDR Class III / FDA 510(k) clearances	Capital console sale + single-use instruments & servicing
Tech-Enabled Care Delivery & Triage	Alan, Cera Care, Sword Health	55% – 70%	Moderate / High; DiGA moats & statutory insurance licenses	Payer per-member-per-month (PMPM) & public tenders
Health AI & Computational Discovery	Owkin, Neko Health	75% – 90%	High; Proprietary multimodal clinical data & biobanks	Multi-year biopharma licenses + screening fees

The ultimate public debuts of these enterprises are shaped by competitive dynamics across international stock exchanges and ongoing strategic consolidation across the healthcare industry.

The Delaware Flip and the Transatlantic Multiple Arbitrage

A persistent dynamic for high-growth European Healthtech scaleups is the valuation multiple arbitrage between European domestic exchanges and the United States public equity markets. Historically, European software and healthcare technology listings on local bourses trade at an implied discount of 15% to 35% relative to comparable peers trading on NASDAQ or the New York Stock Exchange.

Furthermore, the United States market possesses a deep concentration of dedicated life science crossover funds, digital health institutional investors, and sell-side research coverage capable of supporting multi-hundred-million-dollar liquidity requirements.

Consequently, scaleups addressing cross-border end-markets have systematically restructured their parent entities via the "Delaware Flip", transferring corporate legal domiciles to the United States to streamline SEC registration and access deeper North American equity capital. Companies like Oura Health, Sword Health and Owkin have organised corporate operations and leadership structures to execute direct listings in the United States, utilizing NASDAQ as their primary liquidity destination.

Capital Market Reforms Across European Exchanges

European exchanges have enacted comprehensive structural reforms to counter the migration of domestic technology assets to United States exchanges:

United Kingdom Financial Conduct Authority (FCA) Modernisation: The UK FCA enacted substantial reforms to its listing regime that took effect on July 29, 2024. The historical two-tier Premium and Standard segments were replaced by a unified commercial category, the Equity Shares (Commercial Companies) or ESCC regime. The FCA removed historic requirements requiring a three-year financial operating track record and an unqualified clean working capital statement, lowered the public free-float requirement from 25% to 10%, and expanded the flexibility of dual-class share structures (DCSS) with weighted voting rights to permit founders to maintain strategic control. These structural adjustments directly lower the barriers to an LSE Main Market listing for scaleups such as Huma Therapeutics and Cera Care.
Euronext European Common Prospectus: Euronext has harmonized admission guidelines across Paris, Amsterdam, Brussels, and Milan, leveraging the European Common Prospectus framework to streamline cross-border listings and reduce issuance overhead. This allows domestic category leaders like Doctolib and Alan to consolidate pan-European institutional liquidity on their domestic bourses while defending against the compliance costs associated with Sarbanes-Oxley reporting in the United States.
SIX Swiss Exchange Ecosystem: Switzerland provides an established, deep capital market for Medtech platforms, backed by specialized healthcare-focused private wealth and institutional managers, providing an alternative listing home for companies like Distalmotion.

Dual-Track Pressure and Strategic Medtech Consolidation

Given the substantial capital expenditure required to establish global commercial operations and service networks in surgical robotics and high-acuity Medtech, venture-backed scaleups frequently maintain dual-track exit processes. Diversified Medtech conglomerates, including Medtronic, Johnson & Johnson, Stryker and Boston Scientific face pipeline expirations across legacy product lines and are seeking to deploy cash reserves into proven, clinically validated robotic and digital health assets.

Both CMR Surgical and Distalmotion operate formal dual tracks, assessing the net proceeds and volatility of an initial public offering against the execution certainty of a multi billion dollar strategic acquisition. If public market valuations for early stage Medtech remain volatile, these enterprises retain the option to execute accretive trade sales to strategic corporate acquirers rather than navigating public offerings.

Strategic Outlook and Pipeline Conclusions

The European Healthtech, Medtech, and Health AI ecosystem is entering a critical window, characterized by mature scaleups that have aligned their operating models with public market expectations. The era of unconstrained, venture subsidised user acquisition has been replaced by an emphasis on financial durability, margin expansion, and regulatory compliance.

Oura Health stands at the forefront of the near-term pipeline, with active confidential SEC documentation positioning the company for a landmark NASDAQ offering that will test public market appetite for biometric hardware-software integration. Enterprise platform leaders Doctolib, Alan, and Sword Health have demonstrated operational leverage, establishing recurring ARR between $240 million and $900 million while delivering or approaching net corporate profitability.

In parallel, Medtech and Health AI innovators CMR Surgical, Distalmotion, Owkin, Huma Therapeutics, Cera Care, and Neko Health have translated proprietary IP, clinical evidence, and regulatory clearances into defensible market positions.

The distribution of listing venues between London, continental Europe and New York will reflect how effectively European regulatory reforms retain domestic technology scaleups against the capital depth of the United States. Issuers that successfully navigate public listings in this 2026–2027 window will be those that pair clinical data and regulatory barriers with sustainable cash-flow dynamics, setting the public valuation benchmarks for European healthcare technology for the remainder of the decade.

Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics